Authors' objectives: The objective of this Special Report is to review the evidence on the effects of 4 drugs for metastatic castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, abiraterone acetate, and enzalutamide. Two patient indications are considered: patients undergoing first-line systemic therapy and patients undergoing post-docetaxel second-line therapy. This Report seeks evidence on health outcomes such as overall survival, symptoms, quality of life and adverse events. Intermediate outcomes include prostate-specific antigen (PSA) response, objective tumor response, progression-free survival and time to PSA progression. This Report addresses the relative effects of these 4 drugs with head-to-head comparators from randomized, controlled trials (RCTs). The Report also attempts indirect comparisons between these drugs. Finally, the review explores whether there are differences in the effectiveness of these drugs based on patient or treatment characteristics.

Project Status: Completed

Year Published: 2012

URL for published report: http://www.bcbs.com/blueresources/tec/vols/27/27_07.pdf

URL for additional information: http://www.bcbs.com/blueresources/tec/vols/27/castration-resistant-metastatic-prostate-cancer.html

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: BlueCross BlueShield Association

Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321

Contact Name: tec@bcbsa.com

Contact Email: tec@bcbsa.com

Copyright: BlueCross BlueShield Association (BCBS)